The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
April 28th 2025
From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ground.
Dr Andre Goy Previews Key Data on CAR T-Cell Therapy to Be Presented at ASH 2021
December 10th 2021Andre Goy, MD, MS, chairman and executive director of the John Theurer Cancer Center, provides an overview of the emerging data at ASH 2021 on CAR T-cell therapy as a second- and first-line treatment.
Watch
Study Examines Relapse Risk in GVHD After Allo-HCT Using 2 Therapy Options
December 9th 2021Despite the increase in relapse risk, 2-year survival for patients with graft-versus-host disease (GVHD) who received matched sibling donor (MSD) allogeneic hematopoietic cell transplant (allo-HCT) administered post-transplant cyclophosphamide remained similar compared with patients receiving cyclosporine A with methotrexate prophylactically.
Read More
Failed sedation for routine gastrointestinal (GI) endoscopy is extremely rare, warranting a return to endoscopist-directed sedation, rather than costly anesthesia-assisted sedation, as the default sedation standard.
Read More
Pediatric Patients With ASMD Show Significant Improvement in Olipudase Alfa Trial
December 4th 2021Findings from the single-arm, open-label ASCEND-Peds trial suggest olipudase alfa is well-tolerated and may lead to clinically meaningful improvements in patients with acid sphingomyelinase deficiency (ASMD) who do not have neurovisceral manifestations.
Read More
Genomic Profiling Identifies 3 NSCLC Subtypes Predictive of Adjuvant Therapy Outcomes
December 2nd 2021Next-generation sequencing uncovered 3 subtypes of epidermal growth factor receptor–mutant stage 2 and 3 non–small cell lung cancer (NSCLC) that predicted patient outcomes to adjuvant therapy.
Read More
Rituximab Infusion Timing, Dosing and COVID-19 Hospitalization Not Linked, Study Says
December 1st 2021A study examining the relation between rituximab infusion and hospitalization as a result of COVID-19 for patients with multiple sclerosis (MS) found that the 2 were not related, contradicting past research.
Read More
NGS, Prediction Tools Show Similarities Between Metastatic Breast Cancer, Other Advanced Cancers
November 27th 2021Next-generation sequencing (NGS) and the use of prediction tools in 2 patients with a rare form of metastatic breast cancer revealed mutations in malignant phyllodes tumors that are often detected in other advanced cancers, providing insight into potential therapeutic targets for these patients.
Read More
George Van Antwerp: Specialty Drugs Rely on Personalization for Optimal Outcomes
November 24th 2021The high cost of specialty drugs makes it important to use companion diagnostics and other tests to make sure the drug is going to the right patient, said George Van Antwerp, MBA, managing director, Deloitte Consulting.
Watch
Researchers Identify Novel Biomarker, Therapeutic Target for Polycythemia Vera
November 24th 2021The data set included 177 samples from polycythemia vera, essential thrombocytopenia, primary myelofibrosis, and healthy donors, from which the researchers found that MAPK14 was overexpressed in PV samples and was associated with more symptoms and worse outcomes.
Read More
Machine Learning Approach Finds Several Severity-Associated Factors in Atopic Dermatitis
November 23rd 2021Findings of a machine learning-based deep phenotyping approach found a myriad of factors associated with severe disease in atopic dermatitis, including age between 12 and 21 years or older than 52 years, lack of physical activity, and incidence of alopecia areata.
Read More
Study Finds Link Between Ultrasounds, PROs in Patients With RA, Low Disease Activity
November 23rd 2021New research found that residual inflammation in ultrasound images was associated with patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) with low disease activity, but not in patients in remission.
Read More
Dr Robert Hopkin on Emerging Therapeutic, Technological Advancements in Fabry Disease
November 19th 2021Robert J. Hopkin, MD, clinical geneticist, Cincinnati Children's Hospital Medical Center, discusses current and emerging therapeutic and technological advancements in the management of Fabry disease.
Watch